A novel drug delivery system by the global engineering technologies company, Renishaw, was successfully used as part of an extension study to a first-in-human clinical trial for the treatment of Parkinson’s disease.
Renishaw, designed and manufactured the chronic drug delivery system called neuroinfuse , which is composed of up to four catheters that can be accessed via a 3D printed titanium port implanted behind the patient’s ear to aid in safely delivering a novel drug through brain infusion to patients with the neurodegenerative disorder.
Originally created to enable pharmaceuticals to bypass the blood-brain barrier for the ongoing treatment of neurological disorders and brain tumors, neuroinfuse acts as a mechanism to deliver drugs directly into the brain, so that new therapeutic regimes can be developed to treat neurological disorders, using minimal doses for maximum effect, claimed Renishaw. The transcutaneous bone-anchored 3D printed titanium port that is implanted behind […]
I’ve been investigating the rather quiet company Seurat Technologies, which is developing a new metal 3D printing...